Caspofungin: Clinical Trials

2 trials of Caspofungin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 recruiting, 1 withdrawn. 2 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Recruiting 1, Withdrawn 1
Phase 22Recruiting 1, Withdrawn 1

Follow Caspofungin: new trials by email Literature Review of Caspofungin trials Research Report on Caspofungin

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia
Caspofungin Acetate 50 MG, Physiologic saline - Pneumocystis Pneumonia, Pneumocystis Jirovecii Infection
Phase 1 / Phase 2RecruitingUniversity Hospital, Tours1002025-12-022026-10-09
Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients
F901318, Caspofungin - Pulmonary Aspergillosis - Invasive, Acute Myeloid Leukemia
Phase 1 / Phase 2WithdrawnF2G Ltd2017-04-202018-02-15

Conditions studied

Invasive Pulmonary Aspergillosis (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Lung Diseases, Interstitial (1)  ·  Pneumocystis Infections (1)  ·  Pneumonia, Pneumocystis (1)  ·  Respiratory Aspiration (1)

Sponsors

F2G Ltd (1)  ·  University Hospital, Tours (1)

Countries

France (1)

Top investigators

Oliver Cornely, PhD, MD (1)

Results publications

PMID 16304338, PMID 18046534, PMID 20946413, PMID 22548840, PMID 23940606, PMID 26935726, PMID 30776290, PMID 31548210, PMID 31633150, PMID 32194238, PMID 41151592, PMID 9872631

NIH funding

2023 (1)